Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-09-21 4:34 pm Purchase | 2021-09-20 | 13G | Protagonist Therapeutics, Inc. PTGX | Point72 Asset Management, L.P. | 4,329,030 9.100% | 4,329,030 (New Position) | Filing History |
| 2021-02-17 2:23 pm Sale | 2020-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX | Consonance Capital Management LP | 2,729,709 6.380% | -3,328,796 (-54.94%) | Filing History |
| 2021-02-16 2:22 pm Purchase | 2020-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX | Consonance Capital Management LP | 6,058,505 9.990% | 6,058,505 (New Position) | Filing History |
| 2021-02-12 9:17 pm Purchase | 2020-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX | BIOTECHNOLOGY VALUE FUND LP | 4,274,965 9.990% | 1,942,335 (+83.27%) | Filing History |
| 2021-02-12 6:42 pm Purchase | 2020-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX | FARALLON CAPITAL MANAGEMENT LLC | 3,925,000 9.000% | 1,071,902 (+37.57%) | Filing History |
| 2021-02-12 09:36 am Purchase | 2020-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX | RTW INVESTMENTS LP | 3,650,069 8.670% | 1,190,081 (+48.38%) | Filing History |
| 2021-02-11 08:05 am Sale | 2020-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX | ADAGE CAPITAL PARTNERS GP L.L.C. | 1,150,045 2.690% | -1,049,955 (-47.73%) | Filing History |
| 2021-02-08 10:31 am Purchase | 2021-02-05 | 13G | Protagonist Therapeutics, Inc. PTGX | FMR LLC | 6,452,764 15.079% | 2,371,797 (+58.12%) | Filing History |
| 2021-02-02 3:13 pm Purchase | 2020-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX | BlackRock Inc. BLK | 2,591,711 6.200% | 935,470 (+56.48%) | Filing History |
| 2021-02-01 5:41 pm Unchanged | 2020-12-31 | 13G | Protagonist Therapeutics, Inc. PTGX | JOHNSON & JOHNSON JNJ | 2,449,183 5.700% | 0 (Unchanged) | Filing History |
| 2020-06-09 4:32 pm Purchase | 2020-05-31 | 13G | Protagonist Therapeutics, Inc. PTGX | BlackRock Inc. BLK | 1,656,241 4.800% | 94,284 (+6.04%) | Filing History |
| 2020-06-08 4:04 pm Sale | 2020-05-11 | 13D | Protagonist Therapeutics, Inc. PTGX | Lilly Ventures Fund I LLC | 1,559,060 4.500% | -540,422 (-25.74%) | Filing History |
| 2020-05-22 4:30 pm Purchase | 2020-05-13 | 13G | Protagonist Therapeutics, Inc. PTGX | ADAGE CAPITAL PARTNERS GP L.L.C. | 2,200,000 6.390% | 2,200,000 (New Position) | Filing History |